Free Trial

Mannatech (MTEX) Competitors

Mannatech logo
$11.30 +0.80 (+7.62%)
(As of 12/5/2024 ET)

MTEX vs. BYSI, XFOR, IMRX, PASG, ALVR, CLRB, ALRN, CRVO, ITRM, and SPRO

Should you be buying Mannatech stock or one of its competitors? The main competitors of Mannatech include BeyondSpring (BYSI), X4 Pharmaceuticals (XFOR), Immuneering (IMRX), Passage Bio (PASG), AlloVir (ALVR), Cellectar Biosciences (CLRB), Aileron Therapeutics (ALRN), CervoMed (CRVO), Iterum Therapeutics (ITRM), and Spero Therapeutics (SPRO). These companies are all part of the "pharmaceutical products" industry.

Mannatech vs.

BeyondSpring (NASDAQ:BYSI) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability, community ranking and analyst recommendations.

BeyondSpring has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Comparatively, Mannatech has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500.

Mannatech received 123 more outperform votes than BeyondSpring when rated by MarketBeat users. Likewise, 76.43% of users gave Mannatech an outperform vote while only 66.79% of users gave BeyondSpring an outperform vote.

CompanyUnderperformOutperform
BeyondSpringOutperform Votes
185
66.79%
Underperform Votes
92
33.21%
MannatechOutperform Votes
308
76.43%
Underperform Votes
95
23.57%

BeyondSpring has a net margin of 0.00% compared to Mannatech's net margin of -1.26%. BeyondSpring's return on equity of 0.00% beat Mannatech's return on equity.

Company Net Margins Return on Equity Return on Assets
BeyondSpringN/A N/A N/A
Mannatech -1.26%-15.62%-3.76%

Mannatech has higher revenue and earnings than BeyondSpring.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BeyondSpring$1.75M38.53-$21.03MN/AN/A
Mannatech$131.96M0.14-$2.24M-$0.81-12.36

In the previous week, Mannatech had 1 more articles in the media than BeyondSpring. MarketBeat recorded 1 mentions for Mannatech and 0 mentions for BeyondSpring. Mannatech's average media sentiment score of 0.93 beat BeyondSpring's score of 0.00 indicating that Mannatech is being referred to more favorably in the news media.

Company Overall Sentiment
BeyondSpring Neutral
Mannatech Positive

40.3% of BeyondSpring shares are owned by institutional investors. Comparatively, 13.0% of Mannatech shares are owned by institutional investors. 29.3% of BeyondSpring shares are owned by insiders. Comparatively, 41.5% of Mannatech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Mannatech beats BeyondSpring on 8 of the 13 factors compared between the two stocks.

Get Mannatech News Delivered to You Automatically

Sign up to receive the latest news and ratings for MTEX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MTEX vs. The Competition

MetricMannatechMedicinals & botanicals IndustryMedical SectorNASDAQ Exchange
Market Cap$18.82M$1.21B$5.22B$9.16B
Dividend YieldN/AN/A5.72%4.01%
P/E Ratio-12.3627.40101.6214.88
Price / Sales0.147.291,262.2588.47
Price / CashN/A11.2241.5038.06
Price / Book1.772.114.754.94
Net Income-$2.24M-$51.46M$119.18M$224.89M
7 Day Performance27.35%-4.08%2.46%1.84%
1 Month Performance17.76%-10.57%1.97%9.06%
1 Year Performance13.62%1.78%32.04%28.59%

Mannatech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MTEX
Mannatech
1.0981 of 5 stars
$11.30
+7.6%
N/A+19.0%$21.24M$131.96M-13.95250Analyst Forecast
News Coverage
Gap Up
High Trading Volume
BYSI
BeyondSpring
N/A$1.72
-10.9%
N/A+89.4%$67.13M$1.75M0.0080Gap Down
XFOR
X4 Pharmaceuticals
4.1121 of 5 stars
$0.39
-0.8%
$2.88
+637.2%
-53.5%$66.51MN/A-4.3780
IMRX
Immuneering
2.7748 of 5 stars
$2.10
+0.5%
$12.80
+509.5%
-72.3%$65.21M$320,000.00-1.0660
PASG
Passage Bio
3.4652 of 5 stars
$1.04
-8.4%
$7.75
+648.8%
+17.9%$63.93MN/A-0.91130High Trading Volume
ALVR
AlloVir
2.6073 of 5 stars
$0.55
+0.1%
N/A-74.8%$63.41MN/A-0.61110Positive News
Gap Up
CLRB
Cellectar Biosciences
2.3557 of 5 stars
$1.54
-0.3%
$20.00
+1,202.9%
-41.2%$63.35MN/A-0.9010Analyst Forecast
ALRN
Aileron Therapeutics
3.6155 of 5 stars
$2.92
+2.1%
$19.00
+550.7%
-2.9%$63.28MN/A-0.929Positive News
Gap Down
CRVO
CervoMed
1.7095 of 5 stars
$10.20
-5.6%
$50.33
+393.5%
+5.3%$62.93M$7.14M0.004Analyst Forecast
Gap Up
High Trading Volume
ITRM
Iterum Therapeutics
1.7176 of 5 stars
$2.26
+11.9%
$5.00
+121.2%
+13.3%$62.19MN/A-1.1010Short Interest ↑
SPRO
Spero Therapeutics
4.7705 of 5 stars
$1.13
-0.9%
$5.00
+342.5%
-4.1%$61.61M$103.78M16.2946Analyst Forecast
Analyst Revision
News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:MTEX) was last updated on 12/5/2024 by MarketBeat.com Staff
From Our Partners